Biotecnología

Biotecnología

Integreon Global Appoints Michael Hays as President
30/11/2022 - Replaces Maurice Barakat, who will assume the role of Executive Chairman and CEO.
Aptamer Group Opens New State-of-the-Art Facilities
30/11/2022 - New site will help to expand capacity of Aptamer’s Optimer platform to deliver novel binders for the bioprocessing, diagnostic, and drug development sectors.
C4X Discovery, AstraZeneca Enter Potential $402M COPD Alliance
30/11/2022 - The companies will work to develop C4XD’s NRF2 Activator program in COPD and other inflammatory and respiratory illnesses.
Genezen Appoints Jeff Whitmore as Chief Commercial Officer
30/11/2022 - Whitmore has 25 years’ experience in biotechnology.
Lonza, AbTis Partner to Extend Bioconjugation Capabilities
30/11/2022 - To implement AbTis’ AbClick platform into Lonza’s bioconjugation toolbox.
Immutep Enters Clinical Trial Collaboration Merck KGaA and Pfizer
30/11/2022 - To evaluate new combination study of its first-in-class LAG-3 candidate, eftilagimod alpha, and avelumab to treat urothelial cancer.
BigHat Biosciences, Merck Enter AI Research Collaboration
30/11/2022 - To optimize up to three proteins by leveraging BigHat’s platform to synthesize, express, purify, and characterize molecules.
Biocon Completes Acquisition of Viatris' Global Biosimilars Business
30/11/2022 - Creates an integrated, leading global biosimilars enterprise with eight commercialized products.
AstraZeneca to Acquire Neogene Therapeutics in $320M Deal
30/11/2022 - Provides access to next-generation T-cell receptor therapies with promising potential for targeting solid tumors.
Quotient Sciences Partners with Emplicure to Manufacture and Study EMPLI03
30/11/2022 - Emplicure is developing EMPLI03 as an oral buccal tablet with extended-release properties intended for the treatment of moderate to severe pain.
Andelyn Biosciences to Bring First Gene Therapy for Treatment of INAD to Clinical Trials
30/11/2022 - Infantile Neuroaxonal Dystrophy (INAD) is a rare inherited neurological disorder.
Avectas Expands Collaboration with CCRM and OmniaBio Inc.
30/11/2022 - Will enable the development of gene-edited induced pluripotent stem cells using Avectas' non-viral cell engineering platform, SOLUPORE.
Charles River Labs Opens Contract Vivarium Space in Chicago
30/11/2022 - Expands access to AAALAC-accredited, turnkey research program.
Theralink Technologies Achieves CAP Accreditation for Protein Array Lab
30/11/2022 - Becomes the company's first Reverse Phase Protein Array lab in the U.S. with CAP accreditation for its next-gen proteomic services.
Incannex, Eurofins Enter Development & Mfg. Pact for Addiction Disorder Meds
30/11/2022 - Eurofins will provide formulation development and manufacture of chewable CannQuit Nicotine (CannQuit-N) and CannQuit Opioid (CannQuit-O).
Oxford Biomedica Appoints Dr. Frank Mathias as CEO and Board Director
23/11/2022 - Mathias previously served as CEO of Rentschler Biopharma SE, which he successfully developed into a leading global, full-service CDMO.
Regeneron, CytomX Partner on Next-Gen Bispecific Immunotherapies
23/11/2022 - Will Leverage CytomX's Probody therapeutic platform and Regeneron's Veloci-Bi Antibody development platform.
Provention Bio’s TZIELD Approved as First Treatment to Delay Onset of T1D
23/11/2022 - In a clinical trial, in Stage 2 T1D patients, TZIELD delayed the median onset of Stage 3 T1D by approximately 2 years, compared to placebo.
BARDA Invests in Development of Antifungal Treatments
23/11/2022 - Seeks partnerships to develop broad-spectrum next-generation antifungal drugs to treat high-priority fungal infections.
MilliporeSigma to Invest More Than $286M in Biosafety Testing Capacity
23/11/2022 - Expansion creates more than 500 new jobs in Rockville, Maryland.
Teva Pharmaceuticals Appoints Richard Francis CEO
23/11/2022 - Mr. Francis is a seasoned pharmaceutical executive with more than two and a half decades of experience.